Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 9/20 | 0.36 |
| ▸ | CTSS | P25774 | 6/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA7 | P43166 | 2/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6623918 | 0.82 | MEN1 (0.38) | MEN1GAAKMT2ACTSKCTSS | |
| SCHEMBL30464727 | 0.82 | CTSK (0.41) | MEN1GAAKMT2ACTSKCTSS | |
| SCHEMBL939491 | 0.81 | PTPN11 (0.47) | MEN1GAAKMT2ACTSKCTSS | |
| SCHEMBL19787902 | 0.81 | CTSK (0.36) | MEN1GAAKMT2ACTSKCTSS | |
| SCHEMBL1207296 | 0.79 | CTSK (0.36) | MEN1GAAKMT2ACTSKCTSS | |
| SCHEMBL30975132 | 0.78 | CTSK (0.39) | MEN1GAAKMT2ACTSKCTSS | |
| SCHEMBL5728803 | 0.77 | CTSK (0.38) | MEN1GAAKMT2ACTSKCTSS | |
| SCHEMBL6692466 | 0.77 | PTPN11 (0.46) | MEN1GAAKMT2ACTSKCTSS | |
| SCHEMBL18712103 | 0.77 | CTSK (0.38) | MEN1GAAKMT2ACTSKCTSS | |
| SCHEMBL28609057 | 0.76 | EPHX2 (0.35) | MEN1GAAKMT2ACTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017081590-A1 | PROCESS FOR THE PREPARATION OF OMARIGLIPTIN | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2017-05-18 | — | — | WO | disclosed |
| EP-2173724-B1 | QUINAZOLINONE COMPOUNDS AND METHODS OF USE THEREOF | ARQULE INC (US) | 2012-12-05 | — | — | EP | disclosed |
| US-8232285-B2 | Quinazolinone compounds and methods of use thereof | ARQULE, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-20110217300-A1 | Quinazolinone Compounds and Methods of Use Thereof | ARQULE, INC. (US) | 2011-09-08 | — | — | US | disclosed |
| EP-2173724-A2 | QUINAZOLINONE COMPOUNDS AND METHODS OF USE THEREOF | ArQule, Inc. (US) | 2010-04-14 | — | — | EP | disclosed |
| US-20090130097-A1 | Quinazolinone Compounds and Methods of Use Thereof | ARQULE, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| WO-2009002808-A2 | QUINAZOLINONE COMPOUNDS AND METHODS OF USE THEREOF | ARQULE, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110217300-A1 | Quinazolinone Compounds and Methods of Use Thereof | NQO2, NQO1, MKI67 | MEN1 1270/4885GAA 608/4885KMT2A 2190/4885 |
| US-20090130097-A1 | Quinazolinone Compounds and Methods of Use Thereof | NQO2, NQO1, MKI67 | MEN1 1270/4885GAA 608/4885KMT2A 2190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.